MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

Dr Reddy's Laboratories Ltd-ADR

Gesloten

SectorGezondheidszorg

13.24 0.61

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

13.01

Max

13.24

Belangrijke statistieken

By Trading Economics

Inkomsten

1.5B

14B

Verkoop

3.4B

84B

K/W

Sectorgemiddelde

17.587

63.778

EPS

16.936

Dividendrendement

0.72

Winstmarge

16.795

Werknemers

27,048

EBITDA

2.4B

24B

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+38.3% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

0.72%

2.39%

Marktinformatie

By TradingEconomics

Marktkapitalisatie

8.8B

11B

Vorige openingsprijs

12.63

Vorige sluitingsprijs

13.24

Technische score

By Trading Central

Vertrouwen

Bearish Evidence

Dr Reddy's Laboratories Ltd-ADR Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

26 jun 2024, 13:33 UTC

Acquisities, Fusies, Overnames

Haleon to Sell Nicotine-Quitting Aid Business for $634 Million -- Update

26 jun 2024, 12:32 UTC

Acquisities, Fusies, Overnames

Haleon to Sell Nicotine-Quitting Aid Business for $634 Million

25 apr 2024, 10:32 UTC

Winsten

Nestle India Reports Rise in Quarterly Profit, Announces JV With Dr. Reddy's Laboratories

23 jan 2025, 17:46 UTC

Winsten

Dr. Reddy's 3Q Net Attributable to Equity Holders of Parent Company INR14.13B

23 jan 2025, 17:42 UTC

Winsten

Dr. Reddy's 3Q Rev INR83.59B

5 nov 2024, 11:01 UTC

Winsten

Dr. Reddy's Laboratories 1H Rev INR156.89B Vs. INR136.19B >RDY

5 nov 2024, 11:00 UTC

Winsten

Dr. Reddy's Laboratories 1H Net INR26.47B Vs. Net INR28.825B >RDY

5 nov 2024, 10:57 UTC

Winsten

Dr. Reddy's Laboratories 2Q Net INR12.55B Vs. Net INR14.80B >RDY

5 nov 2024, 10:57 UTC

Winsten

Dr. Reddy's Laboratories 2Q Rev INR80.16B Vs. INR68.80B >RDY

26 jun 2024, 11:54 UTC

Acquisities, Fusies, Overnames

Haleon: All Other 2024 Guidance Unchanged

26 jun 2024, 11:54 UTC

Acquisities, Fusies, Overnames

Haleon: Sale Will Dilute 2024 Rev by 0.5%, Adj Oper Pft by 1%

26 jun 2024, 11:52 UTC

Acquisities, Fusies, Overnames

Haleon: Sale Allow For NRT Exit Outside US, Trims Business Complexity

26 jun 2024, 11:51 UTC

Acquisities, Fusies, Overnames

Haleon: Deal Expected to Complete Early 4Q

26 jun 2024, 11:50 UTC

Acquisities, Fusies, Overnames

Haleon: Use of Proceeds Will Be in Line With Capital Allocation Priorities

26 jun 2024, 11:49 UTC

Acquisities, Fusies, Overnames

Haleon: Deal Structure Upfront Cash GBP458M, GBP42M Performance-Based Payable

26 jun 2024, 11:48 UTC

Acquisities, Fusies, Overnames

Haleon: Portfolio Includes Nicotinell, Nicabate, Habitrol and Thrive Available in Gum, Lozenge

26 jun 2024, 11:47 UTC

Acquisities, Fusies, Overnames

Haleon: Deal Worth GBP500M With Additional Proceeds From Inventory Transfer

26 jun 2024, 11:46 UTC

Acquisities, Fusies, Overnames

Haleon to Sell Non-US Nicotine Replacement Therapy Business to Dr. Reddy's Laboratories

7 mei 2024, 10:56 UTC

Winsten

Dr. Reddy's Laboratories 4Q Net INR13.07B Vs. Net INR9.59B >500124.BY

7 mei 2024, 10:55 UTC

Winsten

Dr. Reddy's Laboratories 4Q Rev INR70.83B Vs. INR62.97B >500124.BY

Peer Vergelijking

Prijswijziging

Dr Reddy's Laboratories Ltd-ADR Prognose

Koersdoel

By TipRanks

38.3% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 18.2 USD  38.3%

Hoogste 19.4 USD

Laagste 17 USD

Gebaseerd op 2 Wall Street-analisten die 12-maands prijsdoelen bieden voor Dr Reddy's Laboratories Ltd-ADR - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

2 ratings

2

Buy

0

Hold

0

Sell

Technische score

By Trading Central

13.12 / 13.21Steun & Weerstand

Korte Termijn

Bearish Evidence

Gemiddeld Termijn

Bearish Evidence

Lange Termijn

Weak Bullish Evidence

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Dr Reddy's Laboratories Ltd-ADR

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.